Vedolizumab
Indication
First, second and third-line treatment of moderately to severely active ulcerative colitis (NICE TA342)
NICE TA 342 - Vedolizumab for treating moderately to severely active ulcerative colitis
Red
Brand:
Entyvio
Nice TA:
342
Commissioning responsibility:
CCG
PbR excluded:
Yes
BNF chapter:
Gastro-intestinal system
Background
Vedolizumab is recommended by LSCMMG as a first, second or third line biologic option for treating moderately to severely active ulcerative colitis if: an anti-TNF has failed, cannot be tolerated or is contraindicated.
Recommendation
LSCMMG Recommendation:
Red
Reason for decision:
Specialist medicine
Supporting documents: